No Data
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Quince Therapeutics Announced Online Publication Of Data In Lancet Neurology From Its Phase 3 ATTeST Trial Of Its Lead Asset, Erydex (Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes), For Ataxia-Telangiectasia
Express News | Quince Therapeutics: Expects Potential Nda Submission to FDA & Marketing Authorization Application Submission to EMA in 2026
Express News | Quince Therapeutics: Expects to Report Topline Results in Q4 of 2025
Express News | Quince Therapeutics Announces the Lancet Neurology Publication of Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (a-T)
No Data
No Data
